Your browser doesn't support javascript.
loading
Measuring cognitive impairment and monitoring cognitive decline in Huntington's disease: a comparison of assessment instruments.
Horta-Barba, Andrea; Martinez-Horta, Saul; Pérez-Pérez, Jesús; Puig-Davi, Arnau; de Lucia, Natascia; de Michele, Giuseppe; Salvatore, Elena; Kehrer, Stefanie; Priller, Josef; Migliore, Simone; Squitieri, Ferdinando; Castaldo, Anna; Mariotti, Caterina; Mañanes, Veronica; Lopez-Sendon, Jose Luis; Rodriguez, Noelia; Martinez-Descals, Asunción; Júlio, Filipa; Januário, Cristina; Delussi, Marianna; de Tommaso, Marina; Noguera, Sandra; Ruiz-Idiago, Jesús; Sitek, Emilia J; Wallner, Renata; Nuzzi, Angela; Pagonabarraga, Javier; Kulisevsky, Jaime.
Afiliación
  • Horta-Barba A; Department of Medicine, Autonomous University of Barcelona (UAB), Bellaterra, Spain.
  • Martinez-Horta S; Movement Disorders Unit, Neurology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
  • Pérez-Pérez J; Sant Pau Biomedical Research Institute (IIB Sant Pau), Barcelona, Spain.
  • Puig-Davi A; Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • de Lucia N; European Huntington's Disease Network (EHDN), Ulm, Germany.
  • de Michele G; Department of Medicine, Autonomous University of Barcelona (UAB), Bellaterra, Spain.
  • Salvatore E; Movement Disorders Unit, Neurology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
  • Kehrer S; Sant Pau Biomedical Research Institute (IIB Sant Pau), Barcelona, Spain.
  • Priller J; Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • Migliore S; European Huntington's Disease Network (EHDN), Ulm, Germany.
  • Squitieri F; Department of Medicine, Autonomous University of Barcelona (UAB), Bellaterra, Spain.
  • Castaldo A; Movement Disorders Unit, Neurology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
  • Mariotti C; Sant Pau Biomedical Research Institute (IIB Sant Pau), Barcelona, Spain.
  • Mañanes V; Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • Lopez-Sendon JL; European Huntington's Disease Network (EHDN), Ulm, Germany.
  • Rodriguez N; Movement Disorders Unit, Neurology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
  • Martinez-Descals A; Sant Pau Biomedical Research Institute (IIB Sant Pau), Barcelona, Spain.
  • Júlio F; Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • Januário C; European Huntington's Disease Network (EHDN), Ulm, Germany.
  • Delussi M; European Huntington's Disease Network (EHDN), Ulm, Germany.
  • de Tommaso M; University of Naples "Federico II", Naples, Italy.
  • Noguera S; European Huntington's Disease Network (EHDN), Ulm, Germany.
  • Ruiz-Idiago J; University of Naples "Federico II", Naples, Italy.
  • Sitek EJ; European Huntington's Disease Network (EHDN), Ulm, Germany.
  • Wallner R; University of Naples "Federico II", Naples, Italy.
  • Nuzzi A; European Huntington's Disease Network (EHDN), Ulm, Germany.
  • Pagonabarraga J; Department of Neuropsychiatry, Charité-Universitätsmedizin, Berlin, Germany.
  • Kulisevsky J; European Huntington's Disease Network (EHDN), Ulm, Germany.
J Neurol ; 270(11): 5408-5417, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37462754
ABSTRACT

BACKGROUND:

Progressive cognitive decline is an inevitable feature of Huntington's disease (HD) but specific criteria and instruments are still insufficiently developed to reliably classify patients into categories of cognitive severity and to monitor the progression of cognitive impairment.

METHODS:

We collected data from a cohort of 180 positive gene-carriers 33 with premanifest HD and 147 with manifest HD. Using a specifically developed gold-standard for cognitive status we classified participants into those with normal cognition, those with mild cognitive impairment, and those with dementia. We administered the Parkinson's Disease-Cognitive Rating Scale (PD-CRS), the MMSE and the UHDRS cogscore at baseline, and at 6-month and 12-month follow-up visits. Cutoff scores discriminating between the three cognitive categories were calculated for each instrument. For each cognitive group and instrument we addressed cognitive progression, sensitivity to change, and the minimally clinical important difference corresponding to conversion from one category to another.

RESULTS:

The PD-CRS cutoff scores for MCI and dementia showed excellent sensitivity and specificity ratios that were not achieved with the other instruments. Throughout follow-up, in all cognitive groups, PD-CRS captured the rate of conversion from one cognitive category to another and also the different patterns in terms of cognitive trajectories.

CONCLUSION:

The PD-CRS is a valid and reliable instrument to capture MCI and dementia syndromes in HD. It captures the different trajectories of cognitive progression as a function of cognitive status and shows sensitivity to change in MCI and dementia.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Enfermedad de Huntington / Disfunción Cognitiva Límite: Humans Idioma: En Revista: J Neurol Año: 2023 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Enfermedad de Huntington / Disfunción Cognitiva Límite: Humans Idioma: En Revista: J Neurol Año: 2023 Tipo del documento: Article País de afiliación: España